“…Apart from their well-documented advantages, i.e., excellent bioavailability, low toxicity, long-term safety, and low-cost, one more property of these drugs might be of special interest in the setting of HIV infection and of autoimmune diseases, namely, their ability to prevent/treat several infectious diseases other than malaria. The antimalarials have been proven as being beneficial for several intracellular pathogens, but only intracellular ones that mainly affect individuals with impaired cell-mediated immunity, such as Legionella pneumophila, Histoplasma capsulatum, Francisella tularensis, Penicillium marneffei Cryptococcus neoformans, Bacillus subtilis, Mycobacterium avium, Mycobacterium tuberculosis, Toxoplasma gondii [13-20] and others.…”